Glimepiride Tablets

This product is a second-generation sulfonylurea oral hypoglycemic drug. Its main mechanism of hypoglycemic effect is to stimulate pancreatic β cells to secrete insulin and partially increase the sensitivity of peripheral tissues to insulin. This product binds to and dissociates from insulin receptors faster than glibenclamide and is less likely to cause severe hypoglycemia.

Glimepiride. Its chemical name is: 1-[4-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)-ethyl]-benzenesulfonyl]-3-(trans-4-methylcyclohexyl)-urea.

This product is a white tablet with scratches on it.

Type 2 diabetes.

Take the medication orally as directed by your doctor. For patients with diabetes, there is no fixed dose for glimepiride or any other hypoglycemic drug. Fasting blood sugar and glycosylated hemoglobin must be measured regularly to determine the minimum effective dose of the patient's medication; Measure glycosylated hemoglobin levels to monitor the patient's treatment effect. Usual starting dose: In the initial treatment stage, the starting dose of glimepiride is 1-2 mg once a day, administered at breakfast or the first main meal. Those patients who are sensitive to hypoglycemic drugs should start with 1 mg once a day, and the dose should be adjusted with caution. There is no precise dosage relationship between glimepiride and other oral hypoglycemic drugs. The maximum initial dose of glimepiride does not exceed 2 mg. Usual maintenance dose: The usual maintenance dose is 1-4 mg once a day, and the recommended maximum maintenance dose is 6 mg once a day. After the dose reaches 2 mg, the dose increase is based on the patient's blood sugar changes, and the dose is increased by no more than 2 mg every 1 to 2 weeks.

1. Hypoglycemia. This product can cause hypoglycemia, especially in the elderly and weak patients at the beginning of treatment, irregular eating, drinking and patients with liver and kidney damage. According to reports, the incidence rate is 2%. 2. Digestive system symptoms: nausea, vomiting, diarrhea, and abdominal pain are rare. 3. There are individual cases reported that serum liver transaminase increased. 4. Skin allergic reactions, itching, erythema, and urticaria are rare. 5. Others: headache, fatigue, and dizziness are rare.

1. Patients with a known history of allergy to glimepiride are contraindicated. 2. Patients with diabetic ketoacidosis with or without coma are contraindicated. In this case, insulin should be used for treatment. 3. Pregnant women, women in labor, and breastfeeding women are contraindicated.

Precautions for children: There is no research data on the safety and effectiveness of this product for children. Precautions for pregnancy and lactation: 1. Pregnancy: Glimepiride tablets are contraindicated during pregnancy. Pregnant patients should switch to insulin. Patients planning to become pregnant should notify their doctors. 2. Lactation: Sulfonylurea derivatives, such as glimepiride, can be excreted from breast milk and are contraindicated for lactating women. Precautions for the elderly: No special instructions, or follow the doctor's advice.

1. The effect of this product can be enhanced by using it in combination with salicylates, sulfonamides, phenylbutazone, anti-tuberculosis drugs, tetracyclines, monoamine oxidase inhibitors, beta-receptor blockers, chloramphenicol, coumarins and cyclophosphamide. 2. Chlorpromazine, sympathomimetic drugs, corticosteroids, thyroid hormones, oral contraceptives and niacin preparations can reduce the hypoglycemic effect of this product. 3. This product can reduce the patient's tolerance to alcohol, and alcohol may also enhance the hypoglycemic effect of the drug.

Sealed and protected from light.

2mg

36 months

Guizhou Shengjitang Pharmaceutical Co., Ltd.

• Founded in:

  1996-02-16

• Address:

  Qingzhen City Medical Park, Guiyang City, Guizhou Province

• Tax NO.:

  915201006222407117

• Registered Funds:

  607 million yuan

• Website:

  Log in to view

• Email:

  Log in to view